Floatz logo

Leflunomide

PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer

Deborah DoroshowSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

191 Active assets in the PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Palbociclib
Helwan University
Phase 2BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2BBB
Inno-206
Roswell Park Cancer Institute
Phase 3BB
Atezolizumab
TransThera Sciences (Nanjing), Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Leflunomide is also rated in:

immunoglobulin G4-related sclerosing diseaseDormant
BB
Indicative ·
69 / 100
View asset →
central nervous system neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →